Ambrx Biopharma Long Term Debt 2020-2021 | AMAM
Ambrx Biopharma long term debt from 2020 to 2021. Long term debt can be defined as the sum of all long term debt fields.
| Ambrx Biopharma Annual Long Term Debt (Millions of US $) |
|
|---|---|
| 2021 | $ |
| 2020 | $ |
| 2019 | $ |
| Ambrx Biopharma Quarterly Long Term Debt (Millions of US $) |
|
|---|---|
| 2021-12-31 | |
| 2020-12-31 | |
| 2019-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $0.149B | $0.007B |
| Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $162.213B | 9.87 |
| Bio-Rad Laboratories (BIO.B) | United States | $15.121B | 32.79 |
| QIAGEN (QGEN) | Netherlands | $10.280B | 16.23 |
| Biohaven Pharmaceutical Holding (BHVN) | United States | $10.017B | 0.00 |
| Ginkgo Bioworks Holdings (DNA) | United States | $4.593B | 0.00 |
| Emergent Biosolutions (EBS) | United States | $1.775B | 7.60 |
| Arcus Biosciences (RCUS) | United States | $1.357B | 34.40 |
| Myovant Sciences (MYOV) | United Kingdom | $1.000B | 0.00 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.486B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.360B | 0.00 |
| Zymeworks (ZYME) | Canada | $0.346B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.116B | 23.80 |
| SQZ Biotechnologies (SQZ) | United States | $0.099B | 0.00 |
